caffeine has been researched along with Cognition Disorders in 64 studies
Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "240 infants were randomly allocated to caffeine and aminophylline for apnea of prematurity during February 2012 to January 2015." | 9.24 | Long-term neurodevelopment outcome of caffeine versus aminophylline therapy for apnea of prematurity. ( Jayashree, P; Khurana, S; Lewis, LES; Ramesh Bhat, Y; Shivakumar, M; Sujith Kumar Reddy, GV, 2017) |
| "The current study investigated the effects of repeated caffeine administration on performance and subjective reports of sleepiness and fatigue during 50h extended wakefulness." | 9.22 | Caffeine administration at night during extended wakefulness effectively mitigates performance impairment but not subjective assessments of fatigue and sleepiness. ( Banks, S; Grant, C; Johnson, K; Kamimori, GH; Paech, GM; Pajcin, M; Vedova, CB, 2016) |
| "Very preterm infants are prone to apnea and have an increased risk of death or disability." | 9.16 | Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity. ( Anderson, PJ; Asztalos, EV; Barrington, KJ; Davis, PG; Dewey, D; Doyle, LW; Grunau, RE; Moddemann, D; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2012) |
| " This review explores the relation between caffeine intake, diabetes, cognition and dementia, focusing on type 2 diabetes (T2DM)." | 8.86 | Caffeine, diabetes, cognition, and dementia. ( Biessels, GJ, 2010) |
| " The presence of several bioactive compounds, such as polyphenols and caffeine, implicates coffee as a potential nutritional therapeutic in aging." | 7.79 | Coffee, but not caffeine, has positive effects on cognition and psychomotor behavior in aging. ( Chu, YF; Joseph, JA; Lyle, BJ; Miller, MG; Shukitt-Hale, B, 2013) |
| " In particular, several cross-sectional and longitudinal population-based studies suggested a protective effect of coffee, tea, and caffeine use against late-life cognitive impairment/decline, although the association was not found in all cognitive domains investigated and there was a lack of a distinct dose-response association, with a stronger effect among women than men." | 6.52 | Coffee, tea, and caffeine consumption and prevention of late-life cognitive decline and dementia: a systematic review. ( Barulli, MR; Bonfiglio, C; Guerra, V; Logroscino, G; Osella, A; Panza, F; Pilotto, A; Sabbà, C; Seripa, D; Solfrizzi, V, 2015) |
| "d-galactose has been considered a senescent model for age-related neurodegenerative disease." | 5.42 | Caffeine prevents d-galactose-induced cognitive deficits, oxidative stress, neuroinflammation and neurodegeneration in the adult rat brain. ( Ali, T; Kim, MO; Ullah, F; Ullah, N, 2015) |
| "240 infants were randomly allocated to caffeine and aminophylline for apnea of prematurity during February 2012 to January 2015." | 5.24 | Long-term neurodevelopment outcome of caffeine versus aminophylline therapy for apnea of prematurity. ( Jayashree, P; Khurana, S; Lewis, LES; Ramesh Bhat, Y; Shivakumar, M; Sujith Kumar Reddy, GV, 2017) |
| "The current study investigated the effects of repeated caffeine administration on performance and subjective reports of sleepiness and fatigue during 50h extended wakefulness." | 5.22 | Caffeine administration at night during extended wakefulness effectively mitigates performance impairment but not subjective assessments of fatigue and sleepiness. ( Banks, S; Grant, C; Johnson, K; Kamimori, GH; Paech, GM; Pajcin, M; Vedova, CB, 2016) |
| "Very preterm infants are prone to apnea and have an increased risk of death or disability." | 5.16 | Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity. ( Anderson, PJ; Asztalos, EV; Barrington, KJ; Davis, PG; Dewey, D; Doyle, LW; Grunau, RE; Moddemann, D; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2012) |
| "Observational epidemiological studies such as cross-sectional, case-control, and cohort studies have reported inconsistent findings regarding the association between caffeine intake from coffee or tea and the risk of cognitive disorders such as dementia, Alzheimer's disease, cognitive impairment, and cognitive decline." | 4.91 | Caffeine intake from coffee or tea and cognitive disorders: a meta-analysis of observational studies. ( Kim, YS; Kwak, SM; Myung, SK, 2015) |
| " This review explores the relation between caffeine intake, diabetes, cognition and dementia, focusing on type 2 diabetes (T2DM)." | 4.86 | Caffeine, diabetes, cognition, and dementia. ( Biessels, GJ, 2010) |
| "The reviewed studies support the use of methylphenidate to improve end-of-life patient cognitive functions, particularly in the case of hypoactive delirium." | 4.86 | [Using psychostimulants in end-of-life patients with hypoactive delirium and cognitive disorders: A literature review]. ( Elie, D; Gagnon, B; Gagnon, P; Giguère, A, 2010) |
| "We found no evidence that reduced risk of cognitive decline in women with high caffeine consumption is moderated or confounded by diabetes or depression." | 3.80 | The association between caffeine and cognitive decline: examining alternative causal hypotheses. ( Amieva, H; Ancelin, ML; Carrière, I; Ritchie, K; Rouaud, O, 2014) |
| " The presence of several bioactive compounds, such as polyphenols and caffeine, implicates coffee as a potential nutritional therapeutic in aging." | 3.79 | Coffee, but not caffeine, has positive effects on cognition and psychomotor behavior in aging. ( Chu, YF; Joseph, JA; Lyle, BJ; Miller, MG; Shukitt-Hale, B, 2013) |
| "To examine the association between caffeine intake, cognitive decline, and incident dementia in a community-based sample of subjects aged 65 years and over." | 3.74 | The neuroprotective effects of caffeine: a prospective population study (the Three City Study). ( Ancelin, ML; Barberger-Gateau, P; Carrière, I; Dartigues, JF; de Mendonca, A; Portet, F; Ritchie, K; Rouaud, O, 2007) |
| "Caffeine intake was related to moderately better cognitive maintenance over 5 years in older women with vascular disorders." | 2.78 | Caffeine and cognitive decline in elderly women at high vascular risk. ( Berr, C; Kang, JH; Ritchie, K; Vercambre, MN, 2013) |
| "Data also reflected indirect effects of sleep deprivation that are consistent with an increase in homeostatic sleep drive." | 2.73 | Feasibility and behavioral effects of an at-home multi-night sleep restriction protocol for adolescents. ( Amin, R; Beebe, DW; Fallone, G; Flanigan, M; Godiwala, N; Martin, D; Schaffner, L, 2008) |
| "of total sleep deprivation (9 hr." | 2.73 | Effects of acute caffeine withdrawal on Short Category Test performance in sleep-deprived individuals. ( Balkin, TJ; Kahn-Greene, ET; Kamimori, GH; Killgore, DB; Killgore, WD, 2007) |
| "During each sleep deprivation period subjects received either caffeine or placebo according to a randomized, double-blind cross-over design, and they completed an oral RNG task at 3-h intervals." | 2.72 | Random number generation during sleep deprivation: effects of caffeine on response maintenance and stereotypy. ( Achermann, P; Adam, M; Gottselig, JM; Khatami, R; Landolt, HP; Rétey, JV, 2006) |
| "This review examines the effects of carbohydrates, delivered individually and in combination with caffeine, on a range of cognitive domains and subjective mood." | 2.58 | The Effects of Carbohydrates, in Isolation and Combined with Caffeine, on Cognitive Performance and Mood-Current Evidence and Future Directions. ( Bernard, BN; Louise, D; Louise, LC, 2018) |
| " In particular, several cross-sectional and longitudinal population-based studies suggested a protective effect of coffee, tea, and caffeine use against late-life cognitive impairment/decline, although the association was not found in all cognitive domains investigated and there was a lack of a distinct dose-response association, with a stronger effect among women than men." | 2.52 | Coffee, tea, and caffeine consumption and prevention of late-life cognitive decline and dementia: a systematic review. ( Barulli, MR; Bonfiglio, C; Guerra, V; Logroscino, G; Osella, A; Panza, F; Pilotto, A; Sabbà, C; Seripa, D; Solfrizzi, V, 2015) |
| " While coffee and caffeine are known to enhance short-term memory and cognition, some limited research also suggests that long-term use may protect against cognitive decline or dementia." | 2.50 | Current evidence for the use of coffee and caffeine to prevent age-related cognitive decline and Alzheimer's disease. ( Carman, AJ; Dacks, PA; Fillit, HM; Lane, RF; Shineman, DW, 2014) |
| " We believe that the cognitive benefits of chronic caffeine administration in AD mice are due to caffeine itself, and not metabolites of caffeine; this, because our long-term administration of theophylline to AD mice provided no cognitive benefits." | 2.46 | Caffeine and coffee as therapeutics against Alzheimer's disease. ( Arendash, GW; Cao, C, 2010) |
| "Jet lag and shift work disorder are circadian rhythm sleep disorders which result in sleepiness and can elevate injury risk." | 2.46 | Caffeine for the prevention of injuries and errors in shift workers. ( Blackhall, K; Edwards, PJ; Felix, LM; Ker, K; Roberts, I, 2010) |
| " Although it has been suggested that decrements in cognitive performance are present in the range of a 2 to 3% reduction in body weight, several dose-response studies indicate dehydration levels of 1% may adversely affect cognitive performance." | 2.44 | Hydration and cognition: a critical review and recommendations for future research. ( Lieberman, HR, 2007) |
| "The caffeine (10 mg/kg) was administered by gavage route, once daily, during 7 or 14 consecutive days to investigate the effects of acute or subchronic caffeine treatment on long-term behavioural and cognitive deficits induced by CLP." | 1.48 | Effects of Caffeine on Behavioural and Cognitive Deficits in Rats. ( Assis, MS; Boëchat-Barros, R; Carneiro, FP; Eudes-Filho, J; Faro, LRF; Ferreira, VM; Lima, NT; Marchiori, S; Motoyama, AB; Silva, MV; Soares, AC; Sousa, DN; Souza, GMR, 2018) |
| "Caffeine is an adrenergic antagonist that enhances neuronal activity." | 1.46 | Protective effect of low dose caffeine on psychological stress and cognitive function. ( Akakın, D; Ellek, N; Hamamcı, R; Kasimay Cakir, O; Kayalı, DG; Keleş, H; Özbeyli, D; Salehin, N; Yüksel, M, 2017) |
| "d-galactose has been considered a senescent model for age-related neurodegenerative disease." | 1.42 | Caffeine prevents d-galactose-induced cognitive deficits, oxidative stress, neuroinflammation and neurodegeneration in the adult rat brain. ( Ali, T; Kim, MO; Ullah, F; Ullah, N, 2015) |
| "Caffeine treatment (5 mg/kg/day) began when animals were ≈4 months old, and lasted for 6 months." | 1.38 | Chronic caffeine consumption prevents cognitive decline from young to middle age in rats, and is associated with increased length, branching, and spine density of basal dendrites in CA1 hippocampal neurons. ( Alvarez-Cervera, FJ; Arankowsky-Sandoval, G; Bata-García, JL; Cabrera-Isidoro, S; Flores, G; Góngora-Alfaro, JL; Heredia-López, F; Juárez-Díaz, I; Vila-Luna, L; Vila-Luna, S; Zapata-Vázquez, RE, 2012) |
| "Dementia was diagnosed in 226 men (including 118 AD, 80 VaD), and cognitive impairment in 347." | 1.37 | Coffee intake in midlife and risk of dementia and its neuropathologic correlates. ( Gelber, RP; Masaki, KH; Petrovitch, H; Ross, GW; White, LR, 2011) |
| "The results suggest that long-term use of a low dose of caffeine prevents impairment of short-term memory and E-LTP in acutely sleep-deprived rats." | 1.36 | Chronic caffeine treatment prevents sleep deprivation-induced impairment of cognitive function and synaptic plasticity. ( Aleisa, AM; Alhaider, IA; Alkadhi, KA; Alzoubi, KH; Tran, TT, 2010) |
| "We have recently shown that Alzheimer's disease (AD) transgenic mice given a moderate level of caffeine intake (the human equivalent of 5 cups of coffee per day) are protected from development of otherwise certain cognitive impairment and have decreased hippocampal amyloid-beta (Abeta) levels due to suppression of both beta-secretase (BACE1) and presenilin 1 (PS1)/gamma-secretase expression." | 1.35 | Caffeine reverses cognitive impairment and decreases brain amyloid-beta levels in aged Alzheimer's disease mice. ( Arendash, GW; Cao, C; Citron, BA; Dickson, A; Echeverria, V; Lin, X; Mamcarz, M; Mori, T; Potter, H; Rezai-Zadeh, K; Runfeldt, M; Tane, J, 2009) |
| "Recent research indicates that sleep deprivation impairs decision making." | 1.34 | Caffeine effects on risky decision making after 75 hours of sleep deprivation. ( Balkin, TJ; Kamimori, GH; Killgore, WD; Lipizzi, EL, 2007) |
| "Excessive daytime sleepiness may be associated with an increased risk of developing Parkinson disease." | 1.33 | Excessive daytime sleepiness and subsequent development of Parkinson disease. ( Abbott, RD; Curb, JD; Masaki, KH; Nelson, JS; Petrovitch, H; Ross, GW; Tanner, CM; White, LR, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.56) | 18.7374 |
| 1990's | 1 (1.56) | 18.2507 |
| 2000's | 20 (31.25) | 29.6817 |
| 2010's | 40 (62.50) | 24.3611 |
| 2020's | 2 (3.13) | 2.80 |
| Authors | Studies |
|---|---|
| Fernández, JR | 1 |
| Sweet, ES | 1 |
| Welsh, WJ | 1 |
| Firestein, BL | 1 |
| M Yelanchezian, YM | 1 |
| Waldvogel, HJ | 1 |
| Faull, RLM | 1 |
| Kwakowsky, A | 1 |
| Margolis, RH | 1 |
| Saly, GL | 1 |
| Wilson, RH | 1 |
| Khurana, S | 1 |
| Shivakumar, M | 1 |
| Sujith Kumar Reddy, GV | 1 |
| Jayashree, P | 1 |
| Ramesh Bhat, Y | 1 |
| Lewis, LES | 1 |
| Bernard, BN | 1 |
| Louise, LC | 1 |
| Louise, D | 1 |
| Assis, MS | 1 |
| Soares, AC | 1 |
| Sousa, DN | 1 |
| Eudes-Filho, J | 1 |
| Faro, LRF | 1 |
| Carneiro, FP | 1 |
| Silva, MV | 1 |
| Motoyama, AB | 1 |
| Souza, GMR | 1 |
| Marchiori, S | 1 |
| Lima, NT | 1 |
| Boëchat-Barros, R | 1 |
| Ferreira, VM | 1 |
| Vercambre, MN | 1 |
| Berr, C | 1 |
| Ritchie, K | 5 |
| Kang, JH | 1 |
| Kamchatnov, PR | 1 |
| Silva, CG | 1 |
| Métin, C | 1 |
| Fazeli, W | 1 |
| Machado, NJ | 2 |
| Darmopil, S | 1 |
| Launay, PS | 1 |
| Ghestem, A | 1 |
| Nesa, MP | 1 |
| Bassot, E | 1 |
| Szabó, E | 1 |
| Baqi, Y | 1 |
| Müller, CE | 1 |
| Tomé, AR | 1 |
| Ivanov, A | 1 |
| Isbrandt, D | 1 |
| Zilberter, Y | 1 |
| Cunha, RA | 3 |
| Esclapez, M | 1 |
| Bernard, C | 1 |
| Porciúncula, LO | 1 |
| Sallaberry, C | 1 |
| Mioranzza, S | 1 |
| Botton, PH | 1 |
| Rosemberg, DB | 1 |
| Ancelin, ML | 3 |
| Amieva, H | 1 |
| Rouaud, O | 2 |
| Carrière, I | 3 |
| Carman, AJ | 1 |
| Dacks, PA | 1 |
| Lane, RF | 1 |
| Shineman, DW | 1 |
| Fillit, HM | 1 |
| Beydoun, MA | 1 |
| Beydoun, HA | 1 |
| Gamaldo, AA | 1 |
| Teel, A | 1 |
| Zonderman, AB | 1 |
| Wang, Y | 1 |
| Ioannidis, K | 1 |
| Chamberlain, SR | 1 |
| Müller, U | 1 |
| Kim, YS | 1 |
| Kwak, SM | 1 |
| Myung, SK | 1 |
| Panza, F | 1 |
| Solfrizzi, V | 1 |
| Barulli, MR | 1 |
| Bonfiglio, C | 1 |
| Guerra, V | 1 |
| Osella, A | 1 |
| Seripa, D | 1 |
| Sabbà, C | 1 |
| Pilotto, A | 1 |
| Logroscino, G | 1 |
| Ullah, F | 1 |
| Ali, T | 1 |
| Ullah, N | 1 |
| Kim, MO | 1 |
| Bragança, M | 1 |
| Marinho, M | 1 |
| Marques, J | 1 |
| Moreira, R | 1 |
| Palha, A | 1 |
| Marques-Teixeira, J | 1 |
| Esteves, M | 1 |
| Paech, GM | 1 |
| Banks, S | 1 |
| Pajcin, M | 1 |
| Grant, C | 1 |
| Johnson, K | 1 |
| Kamimori, GH | 3 |
| Vedova, CB | 1 |
| Moreira, A | 1 |
| Diógenes, MJ | 1 |
| de Mendonça, A | 3 |
| Lunet, N | 2 |
| Barros, H | 2 |
| Driscoll, I | 1 |
| Shumaker, SA | 1 |
| Snively, BM | 1 |
| Margolis, KL | 1 |
| Manson, JE | 1 |
| Vitolins, MZ | 1 |
| Rossom, RC | 1 |
| Espeland, MA | 1 |
| Kasimay Cakir, O | 1 |
| Ellek, N | 1 |
| Salehin, N | 1 |
| Hamamcı, R | 1 |
| Keleş, H | 1 |
| Kayalı, DG | 1 |
| Akakın, D | 1 |
| Yüksel, M | 1 |
| Özbeyli, D | 1 |
| Beebe, DW | 1 |
| Fallone, G | 1 |
| Godiwala, N | 1 |
| Flanigan, M | 1 |
| Martin, D | 1 |
| Schaffner, L | 1 |
| Amin, R | 1 |
| Killgore, WD | 4 |
| Muckle, AE | 1 |
| Grugle, NL | 2 |
| Killgore, DB | 3 |
| Balkin, TJ | 4 |
| Kahn-Greene, ET | 2 |
| Arendash, GW | 4 |
| Mori, T | 1 |
| Cao, C | 3 |
| Mamcarz, M | 2 |
| Runfeldt, M | 1 |
| Dickson, A | 1 |
| Rezai-Zadeh, K | 2 |
| Tane, J | 1 |
| Citron, BA | 1 |
| Lin, X | 2 |
| Echeverria, V | 1 |
| Potter, H | 2 |
| Corley, J | 1 |
| Jia, X | 1 |
| Kyle, JA | 1 |
| Gow, AJ | 1 |
| Brett, CE | 1 |
| Starr, JM | 1 |
| McNeill, G | 1 |
| Deary, IJ | 1 |
| Schaefer, A | 1 |
| Sampath, SC | 1 |
| Intrator, A | 1 |
| Min, A | 1 |
| Gertler, TS | 1 |
| Surmeier, DJ | 1 |
| Tarakhovsky, A | 1 |
| Greengard, P | 1 |
| Artero, S | 1 |
| Portet, F | 2 |
| Brickman, A | 1 |
| Muraskin, J | 1 |
| Beanino, E | 1 |
| Santos, C | 1 |
| Azevedo, A | 1 |
| Biessels, GJ | 1 |
| Alhaider, IA | 1 |
| Aleisa, AM | 1 |
| Tran, TT | 1 |
| Alzoubi, KH | 2 |
| Alkadhi, KA | 2 |
| Ker, K | 1 |
| Edwards, PJ | 1 |
| Felix, LM | 1 |
| Blackhall, K | 1 |
| Roberts, I | 1 |
| Elie, D | 1 |
| Gagnon, P | 1 |
| Gagnon, B | 1 |
| Giguère, A | 1 |
| Winckworth, LC | 1 |
| Powell, E | 1 |
| Nebes, RD | 1 |
| Pollock, BG | 1 |
| Halligan, EM | 1 |
| Houck, P | 1 |
| Saxton, JA | 1 |
| Gelber, RP | 1 |
| Petrovitch, H | 2 |
| Masaki, KH | 2 |
| Ross, GW | 2 |
| White, LR | 2 |
| Wang, L | 1 |
| Zhang, C | 1 |
| Bai, G | 1 |
| Nong, J | 1 |
| Sussman, S | 1 |
| Arendash, G | 1 |
| Vila-Luna, S | 1 |
| Cabrera-Isidoro, S | 1 |
| Vila-Luna, L | 1 |
| Juárez-Díaz, I | 1 |
| Bata-García, JL | 1 |
| Alvarez-Cervera, FJ | 1 |
| Zapata-Vázquez, RE | 1 |
| Arankowsky-Sandoval, G | 1 |
| Heredia-López, F | 1 |
| Flores, G | 1 |
| Góngora-Alfaro, JL | 1 |
| Schmidt, B | 1 |
| Anderson, PJ | 1 |
| Doyle, LW | 1 |
| Dewey, D | 1 |
| Grunau, RE | 1 |
| Asztalos, EV | 1 |
| Davis, PG | 1 |
| Tin, W | 1 |
| Moddemann, D | 1 |
| Solimano, A | 1 |
| Ohlsson, A | 1 |
| Barrington, KJ | 1 |
| Roberts, RS | 1 |
| Maitre, NL | 1 |
| Stark, AR | 1 |
| Pandolfo, P | 1 |
| Köfalvi, A | 1 |
| Takahashi, RN | 1 |
| Abdul-Razzak, KK | 1 |
| Khabour, OF | 1 |
| Al-Tuweiq, GM | 1 |
| Alzubi, MA | 1 |
| Moy, GA | 1 |
| McNay, EC | 1 |
| Arab, L | 1 |
| Khan, F | 1 |
| Lam, H | 1 |
| Shukitt-Hale, B | 1 |
| Miller, MG | 1 |
| Chu, YF | 1 |
| Lyle, BJ | 1 |
| Joseph, JA | 1 |
| Johnson-Kozlow, M | 1 |
| Kritz-Silverstein, D | 1 |
| Barrett-Connor, E | 1 |
| Morton, D | 1 |
| Bain, JN | 1 |
| Prendergast, MA | 1 |
| Terry, AV | 1 |
| Arneric, SP | 1 |
| Smith, MA | 1 |
| Buccafusco, JJ | 1 |
| Hall, SS | 1 |
| Smith, AP | 1 |
| Abbott, RD | 1 |
| Tanner, CM | 1 |
| Nelson, JS | 1 |
| Curb, JD | 1 |
| Shimbo, M | 1 |
| Nakamura, K | 1 |
| Jing Shi, H | 1 |
| Kizuki, M | 1 |
| Seino, K | 1 |
| Inose, T | 1 |
| Takano, T | 1 |
| Gottselig, JM | 1 |
| Adam, M | 1 |
| Rétey, JV | 1 |
| Khatami, R | 1 |
| Achermann, P | 1 |
| Landolt, HP | 1 |
| Schleif, W | 1 |
| Jackson, EK | 1 |
| Zacharia, LC | 1 |
| Cracchiolo, JR | 2 |
| Shippy, D | 1 |
| Tan, J | 1 |
| Dall'Igna, OP | 1 |
| Fett, P | 1 |
| Gomes, MW | 1 |
| Souza, DO | 1 |
| Lara, DR | 1 |
| Dartigues, JF | 1 |
| Barberger-Gateau, P | 1 |
| Leighty, RE | 1 |
| Runfeldt, MJ | 1 |
| Berndt, DJ | 1 |
| Schleif, WS | 1 |
| Lieberman, HR | 1 |
| Lipizzi, EL | 1 |
| Norman, D | 1 |
| Bardwell, WA | 1 |
| Loredo, JS | 1 |
| Ancoli-Israel, S | 1 |
| Heaton, RK | 1 |
| Dimsdale, JE | 1 |
| Bernstein, GA | 1 |
| Carroll, ME | 1 |
| Dean, NW | 1 |
| Crosby, RD | 1 |
| Perwien, AR | 1 |
| Benowitz, NL | 1 |
| Akita, I | 1 |
| Suwaki, H | 1 |
| Ikeda, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot, Randomized, Double-blind, Placebo-controlled, Parallel Design Study to Evaluate the Effectiveness and Safety of an Alpinia Galanga Formulation, Theacrine Formulation, and Caffeine Formulation on Fatigue, Mental Acuity, and Cognitive Health Among [NCT05170113] | 79 participants (Actual) | Interventional | 2021-11-02 | Completed | |||
| Vitamin D Status and Intakes and Their Association With Cognitive Trajectory in a Longitudinal Study of Urban Adults[NCT03320109] | 3,720 participants (Actual) | Observational | 2004-08-18 | Completed | |||
| Performance Nutrition for Residents and Fellows Working Overnight Shifts: A Pilot Study[NCT03698123] | 61 participants (Actual) | Interventional | 2018-10-29 | Completed | |||
| A Head-to-Head Comparison of the 2B-Alert Caffeine Optimization Algorithm Versus Standard Caffeine Dosing on Performance During Sleep Deprivation (2B-2)[NCT05588934] | 180 participants (Anticipated) | Interventional | 2023-02-28 | Not yet recruiting | |||
| Piloting an Adaption of Cognitive Behavioral Therapy for Insomnia for Shift Workers (CBTI-Shift)[NCT05965609] | 60 participants (Anticipated) | Interventional | 2023-12-08 | Recruiting | |||
| Efficacy and Safety of Methylxanthines in Very Low Birthweight Infants[NCT00182312] | Phase 3 | 2,000 participants (Anticipated) | Interventional | 1999-10-31 | Completed | ||
| Pharmacokinetics (PK) and Safety of Caffeine in Neonates With Hypoxic Ischemic Encephalopathy Receiving Therapeutic Hypothermia[NCT05295784] | Phase 1 | 18 participants (Anticipated) | Interventional | 2024-06-30 | Not yet recruiting | ||
| Longitudinal Study to Assess the Effects of Whole Coffee Cherry Extract (WCCE)[NCT04986956] | 323 participants (Actual) | Interventional | 2022-02-01 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
15 reviews available for caffeine and Cognition Disorders
| Article | Year |
|---|---|
Neuroprotective Effect of Caffeine in Alzheimer's Disease.
Topics: Alzheimer Disease; Animals; Caffeine; Coffee; Cognition Disorders; Humans; Neuroprotective Agents | 2022 |
The Effects of Carbohydrates, in Isolation and Combined with Caffeine, on Cognitive Performance and Mood-Current Evidence and Future Directions.
Topics: Academic Performance; Affect; Animals; Caffeine; Cognition; Cognition Disorders; Dietary Carbohydrat | 2018 |
The Janus face of caffeine.
Topics: Animals; Behavior, Animal; Brain; Caffeine; Central Nervous System Stimulants; Cognition Disorders; | 2013 |
Current evidence for the use of coffee and caffeine to prevent age-related cognitive decline and Alzheimer's disease.
Topics: Aging; Alzheimer Disease; Animals; Caffeine; Coffee; Cognition; Cognition Disorders; Humans; Memory, | 2014 |
Epidemiologic studies of modifiable factors associated with cognition and dementia: systematic review and meta-analysis.
Topics: Alcohol Drinking; Alzheimer Disease; Antioxidants; Caffeine; Cognition; Cognition Disorders; Dementi | 2014 |
Ostracising caffeine from the pharmacological arsenal for attention-deficit hyperactivity disorder--was this a correct decision? A literature review.
Topics: Attention Deficit Disorder with Hyperactivity; Brain; Caffeine; Cognition Disorders; Humans; Puriner | 2014 |
Caffeine intake from coffee or tea and cognitive disorders: a meta-analysis of observational studies.
Topics: Alzheimer Disease; Caffeine; Case-Control Studies; Coffee; Cognition Disorders; Cohort Studies; Deme | 2015 |
Coffee, tea, and caffeine consumption and prevention of late-life cognitive decline and dementia: a systematic review.
Topics: Alzheimer Disease; Caffeine; Coffee; Cognition; Cognition Disorders; Cognitive Dysfunction; Dementia | 2015 |
Caffeine, diabetes, cognition, and dementia.
Topics: Animals; Caffeine; Central Nervous System Stimulants; Coffee; Cognition Disorders; Dementia; Diabete | 2010 |
Caffeine and coffee as therapeutics against Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Caffeine; C | 2010 |
Caffeine for the prevention of injuries and errors in shift workers.
Topics: Accidents, Occupational; Caffeine; Central Nervous System Stimulants; Cognition Disorders; Humans; N | 2010 |
[Using psychostimulants in end-of-life patients with hypoactive delirium and cognitive disorders: A literature review].
Topics: Aged; Caffeine; Central Nervous System Stimulants; Cognition Disorders; Confusion; Delirium; Depress | 2010 |
Question 1 Does caffeine treatment for apnoea of prematurity improve neurodevelopmental outcome in later life?
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Cognition Disorders; Developmental Disabilities; | 2010 |
Epidemiologic evidence of a relationship between tea, coffee, or caffeine consumption and cognitive decline.
Topics: Beverages; Caffeine; Coffee; Cognition; Cognition Disorders; Female; Humans; Male; Nutrition Assessm | 2013 |
Hydration and cognition: a critical review and recommendations for future research.
Topics: Caffeine; Central Nervous System Stimulants; Cognition; Cognition Disorders; Dehydration; Dose-Respo | 2007 |
9 trials available for caffeine and Cognition Disorders
| Article | Year |
|---|---|
Long-term neurodevelopment outcome of caffeine versus aminophylline therapy for apnea of prematurity.
Topics: Aminophylline; Apnea; Caffeine; Child Development; Cognition Disorders; Developmental Disabilities; | 2017 |
Caffeine and cognitive decline in elderly women at high vascular risk.
Topics: Aged; Aging; Caffeine; Central Nervous System Stimulants; Cerebrovascular Disorders; Cognition; Cogn | 2013 |
Caffeine administration at night during extended wakefulness effectively mitigates performance impairment but not subjective assessments of fatigue and sleepiness.
Topics: Caffeine; Cognition Disorders; Double-Blind Method; Drug Administration Schedule; Fatigue; Female; H | 2016 |
Relationships Between Caffeine Intake and Risk for Probable Dementia or Global Cognitive Impairment: The Women's Health Initiative Memory Study.
Topics: Aged; Caffeine; Cognition Disorders; Estrogen Replacement Therapy; Female; Humans; Incidence; Memory | 2016 |
Feasibility and behavioral effects of an at-home multi-night sleep restriction protocol for adolescents.
Topics: Adolescent; Attention; Body Mass Index; Caffeine; Central Nervous System Stimulants; Cognition Disor | 2008 |
Sustaining executive functions during sleep deprivation: A comparison of caffeine, dextroamphetamine, and modafinil.
Topics: Adolescent; Adult; Arousal; Attention; Benzhydryl Compounds; Caffeine; Central Nervous System Stimul | 2009 |
Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity.
Topics: Apnea; Blindness; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Child Development; Ch | 2012 |
Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity.
Topics: Apnea; Blindness; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Child Development; Ch | 2012 |
Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity.
Topics: Apnea; Blindness; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Child Development; Ch | 2012 |
Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity.
Topics: Apnea; Blindness; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Child Development; Ch | 2012 |
Random number generation during sleep deprivation: effects of caffeine on response maintenance and stereotypy.
Topics: Adult; Arousal; Caffeine; Central Nervous System Stimulants; Cognition Disorders; Double-Blind Metho | 2006 |
Effects of acute caffeine withdrawal on Short Category Test performance in sleep-deprived individuals.
Topics: Adult; Caffeine; Cognition Disorders; Concept Formation; Double-Blind Method; Drug Combinations; Eth | 2007 |
40 other studies available for caffeine and Cognition Disorders
| Article | Year |
|---|---|
Identification of small molecule compounds with higher binding affinity to guanine deaminase (cypin) than guanine.
Topics: Binding Sites; Cognition Disorders; Energy Metabolism; Guanine; Guanine Deaminase; Humans; Kinetics; | 2010 |
Ambient Noise Monitoring during Pure-Tone Audiometry.
Topics: Adult; Audiometry; Audiometry, Pure-Tone; Auditory Threshold; Caffeine; Cognition Disorders; Humans; | 2022 |
Effects of Caffeine on Behavioural and Cognitive Deficits in Rats.
Topics: Animals; Behavior, Animal; Caffeine; Cognition; Cognition Disorders; Disease Models, Animal; Male; M | 2018 |
[Vasobral in the treatment of brain lesions: views of physicians and patients].
Topics: Caffeine; Cerebrovascular Disorders; Cognition; Cognition Disorders; Dihydroergotoxine; Drug Combina | 2013 |
Adenosine receptor antagonists including caffeine alter fetal brain development in mice.
Topics: Aging; Animals; Animals, Newborn; Brain; Caffeine; Cell Movement; Cognition Disorders; Disease Susce | 2013 |
The association between caffeine and cognitive decline: examining alternative causal hypotheses.
Topics: Aged; Aged, 80 and over; Body Mass Index; Caffeine; Coffee; Cognition; Cognition Disorders; Cross-Se | 2014 |
Caffeine prevents d-galactose-induced cognitive deficits, oxidative stress, neuroinflammation and neurodegeneration in the adult rat brain.
Topics: Aging; Animals; Antioxidants; Brain; Caffeine; Cognition Disorders; Disease Models, Animal; Galactos | 2015 |
The influence of espresso coffee on neurocognitive function in HIV-infected patients.
Topics: Adult; Antiretroviral Therapy, Highly Active; Attention; Caffeine; Coffee; Cognition; Cognition Diso | 2016 |
Chocolate Consumption is Associated with a Lower Risk of Cognitive Decline.
Topics: Aged; Body Mass Index; Caffeine; Central Nervous System Stimulants; Chi-Square Distribution; Chocola | 2016 |
Protective effect of low dose caffeine on psychological stress and cognitive function.
Topics: Animals; Caffeine; Cats; Central Nervous System Stimulants; Cognition Disorders; Disease Models, Ani | 2017 |
Sex differences in cognitive estimation during sleep deprivation: effects of stimulant countermeasures.
Topics: Adenosine; Adult; Benzhydryl Compounds; Caffeine; Central Nervous System Stimulants; Cognition; Cogn | 2008 |
Caffeine reverses cognitive impairment and decreases brain amyloid-beta levels in aged Alzheimer's disease mice.
Topics: Age Factors; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Brai | 2009 |
Caffeine consumption and cognitive function at age 70: the Lothian Birth Cohort 1936 study.
Topics: Aged; Aging; Caffeine; Child; Coffee; Cognition; Cognition Disorders; Cohort Studies; Drinking Behav | 2010 |
Control of cognition and adaptive behavior by the GLP/G9a epigenetic suppressor complex.
Topics: Adaptation, Physiological; Animals; Animals, Newborn; Behavior, Animal; Benzazepines; Body Weight; C | 2009 |
Caffeine, cognitive functioning, and white matter lesions in the elderly: establishing causality from epidemiological evidence.
Topics: Aged; Aged, 80 and over; Brain; Caffeine; Central Nervous System Stimulants; Cognition Disorders; Fe | 2010 |
Caffeine intake is associated with a lower risk of cognitive decline: a cohort study from Portugal.
Topics: Aged; Caffeine; Central Nervous System Stimulants; Coffee; Cognition Disorders; Cohort Studies; Conf | 2010 |
Chronic caffeine treatment prevents sleep deprivation-induced impairment of cognitive function and synaptic plasticity.
Topics: Animals; Behavior, Animal; Caffeine; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Central Ner | 2010 |
Cognitive slowing associated with elevated serum anticholinergic activity in older individuals is decreased by caffeine use.
Topics: Aged; Caffeine; Cholinergic Antagonists; Cognition; Cognition Disorders; Drug Antagonism; Female; Hu | 2011 |
Coffee intake in midlife and risk of dementia and its neuropathologic correlates.
Topics: Age Factors; Aged; Aged, 80 and over; Alzheimer Disease; Asian; Brain; Caffeine; Case-Control Studie | 2011 |
Caffeine synergizes with another coffee component to increase plasma GCSF: linkage to cognitive benefits in Alzheimer's mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Analysis of Variance; Anim | 2011 |
Chronic caffeine consumption prevents cognitive decline from young to middle age in rats, and is associated with increased length, branching, and spine density of basal dendrites in CA1 hippocampal neurons.
Topics: Aging; Animals; Anxiety; CA1 Region, Hippocampal; Caffeine; Central Nervous System Stimulants; Cogni | 2012 |
Neuroprotection for premature infants?: another perspective on caffeine.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Cognition Disorders; Female; Humans; Infant, Pre | 2012 |
Caffeine regulates frontocorticostriatal dopamine transporter density and improves attention and cognitive deficits in an animal model of attention deficit hyperactivity disorder.
Topics: Animals; Attention; Attention Deficit Disorder with Hyperactivity; Caffeine; Cognition Disorders; Co | 2013 |
Caffeine prevents cognitive impairment induced by chronic psychosocial stress and/or high fat-high carbohydrate diet.
Topics: Analysis of Variance; Animals; Body Weight; Caffeine; Central Nervous System Stimulants; Cognition D | 2013 |
Caffeine prevents weight gain and cognitive impairment caused by a high-fat diet while elevating hippocampal BDNF.
Topics: Analysis of Variance; Animals; Blood Glucose; Brain-Derived Neurotrophic Factor; Caffeine; Central N | 2013 |
Coffee, but not caffeine, has positive effects on cognition and psychomotor behavior in aging.
Topics: Aging; Animals; Behavior, Animal; Beverages; Caffeine; Central Nervous System Stimulants; Coffee; Co | 2013 |
Coffee consumption and cognitive function among older adults.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Caffeine; California; Coffee; Cognition; Cogni | 2002 |
Enhanced attention in rhesus monkeys as a common factor for the cognitive effects of drugs with abuse potential.
Topics: Animals; Atomoxetine Hydrochloride; Attention; Caffeine; Cognition; Cognition Disorders; Color Perce | 2003 |
The quest for a smart pill.
Topics: Alzheimer Disease; Animals; Behavior, Animal; Benzhydryl Compounds; Caffeine; Central Nervous System | 2003 |
Caffeine at work.
Topics: Accidents; Adolescent; Adult; Attention; Caffeine; Cognition Disorders; Female; Humans; Male; Middle | 2005 |
Excessive daytime sleepiness and subsequent development of Parkinson disease.
Topics: Aged; Aged, 80 and over; Aging; Brain; Caffeine; Causality; Cognition Disorders; Cohort Studies; Com | 2005 |
Green tea consumption in everyday life and mental health.
Topics: Adult; Aged; Beverages; Caffeine; Cognition Disorders; Confidence Intervals; Cross-Sectional Studies | 2005 |
Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain beta-amyloid production.
Topics: Adenosine; Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; | 2006 |
Caffeine and adenosine A(2a) receptor antagonists prevent beta-amyloid (25-35)-induced cognitive deficits in mice.
Topics: Adenosine A2 Receptor Antagonists; Alzheimer Disease; Amnesia; Amyloid beta-Peptides; Animals; Avoid | 2007 |
The neuroprotective effects of caffeine: a prospective population study (the Three City Study).
Topics: Aged; Aged, 80 and over; Agnosia; AIDS Arteritis, Central Nervous System; Amyloid beta-Peptides; Caf | 2007 |
Use of artificial neural networks to determine cognitive impairment and therapeutic effectiveness in Alzheimer's transgenic mice.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Caffeine; Central Nervous System Stimula | 2008 |
Caffeine effects on risky decision making after 75 hours of sleep deprivation.
Topics: Adult; Analysis of Variance; Arousal; Caffeine; Cognition Disorders; Decision Making; Female; Gambli | 2007 |
Caffeine intake is independently associated with neuropsychological performance in patients with obstructive sleep apnea.
Topics: Adult; Aged; Body Mass Index; Caffeine; Central Nervous System Stimulants; Cognition Disorders; Fema | 2008 |
Caffeine withdrawal in normal school-age children.
Topics: Analysis of Variance; Attention; Caffeine; Central Nervous System Stimulants; Child; Cognition Disor | 1998 |
[Clouding of consciousness on the withdrawal of caffeine and sodium benzoate].
Topics: Benzoates; Benzoic Acid; Caffeine; Cognition Disorders; Consciousness Disorders; Humans; Male; Middl | 1988 |